Allterum Therapeutics is a private, preclinical-stage biotech founded in 2018 and incubated by Fannin, an early-stage life sciences development group. The company is advancing 4A10, an anti-CD127 monoclonal antibody in-licensed from the National Cancer Institute (NCI), to address critical unmet needs in relapsed/refractory hematologic cancers, particularly pediatric T-cell ALL. With strong academic collaborations, Orphan Drug Designation for its lead program, and non-dilutive grant funding from CPRIT, Allterum is positioned to advance its lead candidate toward clinical trials for a patient population with very poor prognosis and limited treatment options.
OncologyHematologic Malignancies
Technology Platform
Monoclonal antibody platform targeting the IL-7 signaling axis via CD127 (IL-7Rα).
Opportunities
The primary opportunity is addressing the critical unmet need in relapsed/refractory T-cell ALL, a rare pediatric cancer with poor prognosis and limited treatments, supported by Orphan Drug Designation.
Success here could enable expansion into larger markets of other CD127-expressing hematologic malignancies and solid tumors, representing up to 80,000 annual cases.
The Rare Pediatric Disease Designation also offers the potential for a valuable Priority Review Voucher upon approval.
Risk Factors
Key risks include the high failure rate of preclinical assets in clinical translation, the company's binary dependence on a single lead program (4A10), and the need to secure substantial additional funding for costly clinical trials.
The company also faces competition in the broader immuno-oncology landscape and operational complexity in managing multiple high-profile academic collaborations.
Competitive Landscape
In the specific niche of relapsed/refractory T-ALL, direct competition is limited, with nelarabine being the only recently approved drug. However, the broader field of targeted therapies for hematologic cancers is highly competitive, with numerous companies developing CAR-T therapies, bispecific antibodies, and other targeted agents for leukemias and lymphomas. Allterum's differentiation lies in its novel mechanism targeting the IL-7Rα axis.
